Showing results (1311-1320 of 1,373) with videos related to
Sort By:
Pageof 138
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2019
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple MyelomaAurore Perrot, Valérie Lauwers-Cances, Elodie Tournay, et al.Haematologica|March 31, 2022
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Wojciech Legiec, et al.Leukemia|August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trialThierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.Leukemia|February 27, 2025
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomesThierry Facon, Philippe Moreau, Katja Weisel, et al.Thrombosis and Haemostasis|August 2, 2013
MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugsXavier Leleu, Philippe Rodon, Cyrille Hulin, et al.Blood|November 14, 2022
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factorAnaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, et al.Blood|December 18, 2025
Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor loadCathelijne Fokkema, Luca Bertamini, Madelon M E de Jong, et al.Leukemia|January 2, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIAThierry Facon, Gordon Cook, Saad Z Usmani, et al.Blood|January 25, 2012
IMWG consensus on maintenance therapy in multiple myelomaHeinz Ludwig, Brian G M Durie, Philip McCarthy, et al.Pageof 138